Compare Ascendis Pharma A/S (ASND) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Zillow Group Inc Class C — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Zillow Group Inc Class C trades at $32.39 (market cap $7.36B). The key difference: Ascendis Pharma A/S is far larger — about 2.4× Zillow Group Inc Class C's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals.
| ASND | Z | |
|---|---|---|
Market Cap | $17.74B | $7.36B |
Sector | Health | Media |
52-Week High | $277.18 | $90.35 |
52-Week Low | $163.32 | $29.41 |
Enterprise Value | $18.11B | $7.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Zillow Group (Z) trades at $32.19, down 3.74% on the day. The stock shows mixed technical signals with a neutral overall stance. Fundamentally, the company reported revenue of $2.58 billion in 2025 with a net income of $23 million, marking a return to profitability. However, a high P/E ratio of 128.76 indicates significant growth expectations are priced in. Recent news is dominated by multiple securities class action lawsuits filed against the company.
The outlook is clouded by legal risks, though analyst consensus remains optimistic with a $63 price target. The primary opportunity lies in the company's strong revenue growth and high gross margins, but investors must weigh this against the overhang from litigation and the stock's demanding valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
